요관 스텐트 시장 규모, 점유율 및 동향 분석 보고서 : 소재별, 유형별, 코팅별, 용도별, 최종 용도별, 지역별 및 부문별 예측(2026-2033년)

Ureteral Stents Market Summary

The global ureteral stents market size was valued at USD 687.6 million in 2025 and is projected to grow from USD 722.4 million in 2026 to USD 1,108.3 million by 2033, at a CAGR of 6.3% from 2026 to 2033. North America dominated the market, accounting for the largest revenue share of 34.6% in 2025.

The growth of the global ureteral stents industry is driven by the rising prevalence of kidney stone disease, ureteral obstruction, chronic kidney disease, and urological cancers, as well as the increasing adoption of minimally invasive endourological procedures such as ureteroscopy and laser lithotripsy.

Technological advancements are playing a significant role in the market growth, with manufacturers focusing on improving patient comfort, extending indwelling time, and reducing complications such as encrustation, infection, and stent-related pain. Recent innovations include hydrophilic and antimicrobial coatings, advanced silicone and hybrid polymer materials, metallic stents for long-term ureteral obstruction, drug-eluting stents, and biodegradable stents that eliminate the need for secondary removal procedures. Digital technologies are also emerging, including electronic stent tracking systems to prevent forgotten stents and smart monitoring solutions for early detection of complications.

For instance, in April 2025, the U.S. FDA granted 510(k) clearance to Boston Scientific Corporation for updates to its Percuflex Ureteral Stent, Percuflex Plus Ureteral Stent, Polaris Ultra Ureteral Stent, Tria Firm Ureteral Stent, Tria Soft Ureteral Stent, and Contour Ureteral Stent portfolio, reflecting continued innovation in stent design and performance . Furthermore, in June 2026, the European Association of Urology (EAU) Endourology Section published a comprehensive review highlighting ongoing developments in advanced materials, coating technologies, drug-eluting systems, biodegradable stents, and ureteral stent technologies to reduce patient morbidity and improve long-term clinical outcomes. These continuous technological advancements are expected to support the sustained market growth over the forecast period.

Global Ureteral Stents Market Report Segmentation

This report forecasts revenue growth at the global, regional & country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global ureteral stents market report based on material type, type, coating, application, end-use, and region:

• Material Type Outlook (Revenue, USD Million, 2021 - 2033)
• Metallic Stents
• Polymer Stents
  • Silicone Stents
  • Polyurethane Stents
  • Hybrid Stents
• Type Outlook (Revenue, USD Million, 2021 - 2033)
• Open Ended
• Closed Ended
• Double J Stents
• Multiloop Stents
• Coating Outlook (Revenue, USD Million, 2021 - 2033)
• Coated
• Uncoated
• Application Outlook (Revenue, USD Million, 2021 - 2033)
• Kidney Stones
• Kidney Transplantation
• Tumors
• Urinary Incontinence
• Others
• End-use Outlook (Revenue, USD Million, 2021 - 2033)
• Hospitals
• Ambulatory Surgery Centers (ASCs)
• Specialty Urology Clinics
• Regional Outlook (Revenue, USD Million, 2021-2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Thailand
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
  • 1.1.1. Material Type
  • 1.1.2. Type
  • 1.1.3. Coating
  • 1.1.4. Application
  • 1.1.5. End Use
  • 1.1.6. Regional scope
  • 1.1.7. Estimates and forecast timeline
• 1.2. Market Definitions
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased Database
  • 1.4.2. GVR's Internal Database
• 1.5. Details of primary research
  • 1.5.1. Data for primary interviews in North America
  • 1.5.2. Data for primary interviews in Europe
  • 1.5.3. Data for primary interviews in Asia Pacific
  • 1.5.4. Data for primary interviews in Latin America
  • 1.5.5. Data for Primary interviews in MEA
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.1.1. Approach 1: Commodity flow approach
  • 1.7.2. Volume price analysis (Model 2)
    • 1.7.2.1. Approach 2: Volume price analysis
• 1.8. Research Scope and Assumptions
  • 1.8.1. List of Secondary Sources
  • 1.8.2. List of Primary Sources
  • 1.8.3. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Ureteral Stents Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Drivers Analysis
    • 3.2.1.1. Rising global prevalence of kidney stone disease (urolithiasis)
    • 3.2.1.2. Growing adoption of minimally invasive ureteroscopy and endourological procedures
    • 3.2.1.3. Technological advancements in ureteral stent materials and coatings
    • 3.2.1.4. Continued regulatory support and product innovation through the FDA 510(k) pathway
  • 3.2.2. Market Restraints Analysis
    • 3.2.2.1. High incidence of stent-related symptoms, including pain, urinary urgency, infection, and reduced quality of life
    • 3.2.2.2. Limited high-quality comparative clinical evidence for several novel coated and specialty ureteral stents
  • 3.2.3. Market Opportunity Analysis
    • 3.2.3.1. Expansion of metallic stent use in patients with malignant ureteral obstruction
    • 3.2.3.2. Integration of digital ureteral stent tracking and reminder systems to prevent forgotten stents
    • 3.2.3.3. Increasing investment in endourology services across emerging healthcare markets
    • 3.2.3.4. Development of next-generation anti-encrustation and anti-biofilm coated ureteral stents
  • 3.2.4. Market Challenge Analysis
    • 3.2.4.1. Persistent risk of stent encrustation during prolonged indwelling periods
    • 3.2.4.2. Achieving an optimal balance between patient comfort and mechanical performance
• 3.3. Ureteral Stents Market Analysis Tools
  • 3.3.1. Porter's Analysis
    • 3.3.1.1. Bargaining power of the suppliers
    • 3.3.1.2. Bargaining power of the buyers
    • 3.3.1.3. Threats of substitution
    • 3.3.1.4. Threats from new entrants
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Economic and Social landscape
    • 3.3.2.3. Technological landscape
    • 3.3.2.4. Environmental landscape
    • 3.3.2.5. Legal landscape

Chapter 4. Ureteral Stents Market: Material Type Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Global Ureteral Stents Market: Material Type Movement Analysis, 2025 & 2033 (USD Million)
• 4.3. Global Ureteral Stents Market Size & Trend Analysis, by Material Type, 2021 to 2033 (USD Million)
• 4.4. Metallic Stents
  • 4.4.1. Metallic stents market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• 4.5. Polymer Stents
  • 4.5.1. Polymer stents market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • 4.5.2. Silicone Stents
    • 4.5.2.1. Silicone stents market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • 4.5.3. Polyurethane Stents
    • 4.5.3.1. Polyurethane stents market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • 4.5.4. Hybrid Stents
    • 4.5.4.1. Hybrid stents market revenue estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 5. Ureteral Stents Market: Type Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Global Ureteral Stents Market: Type Movement Analysis, 2025 & 2033 (USD Million)
• 5.3. Global Ureteral Stents Market Size & Trend Analysis, by Type, 2021 to 2033 (USD Million)
• 5.4. Open Ended
  • 5.4.1. Open-ended market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• 5.5. Close Ended
  • 5.5.1. Closed-ended market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• 5.6. Double J Stents
  • 5.6.1. Double J stents market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• 5.7. Multiloop Stents
  • 5.7.1. Multiloop stents market revenue estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 6. Ureteral Stents Market: Coating Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Global Ureteral Stents Market: Coating Movement Analysis, 2025 & 2033 (USD Million)
• 6.3. Global Ureteral Stents Market Size & Trend Analysis, by Coating, 2021 to 2033 (USD Million)
• 6.4. Coated
  • 6.4.1. Coated market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• 6.5. Uncoated
  • 6.5.1. Uncoated market revenue estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 7. Ureteral Stents Market: Application Estimates & Trend Analysis

• 7.1. Segment Dashboard
• 7.2. Global Ureteral Stents Market: Application Movement Analysis, 2025 & 2033 (USD Million)
• 7.3. Global Ureteral Stents Market Size & Trend Analysis, by Application 2021 to 2033 (USD Million)
• 7.4. Kidney Stones
  • 7.4.1. Kidney stones market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• 7.5. Kidney Transplantation
  • 7.5.1. Kidney transplantation market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• 7.6. Tumors
  • 7.6.1. Tumors market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• 7.7. Urinary Incontinence
  • 7.7.1. Urinary incontinence market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• 7.8. Others
  • 7.8.1. Others market revenue estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 8. Ureteral Stents Market: End Use Estimates & Trend Analysis

• 8.1. Segment Dashboard
• 8.2. Global Ureteral Stents Market: End Use Movement Analysis, 2025 & 2033 (USD Million)
• 8.3. Global Ureteral Stents Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million)
• 8.4. Hospitals
  • 8.4.1. Hospitals market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• 8.5. Ambulatory Surgery Centers (ASCs)
  • 8.5.1. Ambulatory Surgery Centers (ASCs) market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• 8.6. Specialty Urology Clinics
  • 8.6.1. Specialty urology clinics market revenue estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 9. Ureteral Stents Market: Regional Estimates & Trend Analysis by Material Type, Type, Coating, Application, and End Use

• 9.1. Regional Dashboard
• 9.2. Market Size and Trend Analysis, 2021 to 2033
• 9.3. North America
  • 9.3.1. North America ureteral stents market estimates and forecasts, 2021 - 2033 (USD Million)
  • 9.3.2. U.S.
    • 9.3.2.1. Key country dynamics
    • 9.3.2.2. Competitive scenario
    • 9.3.2.3. Regulatory framework
    • 9.3.2.4. Reimbursement scenario
    • 9.3.2.5. U.S. ureteral stents market estimates and forecasts, 2021 - 2033 (USD Million)
  • 9.3.3. Canada
    • 9.3.3.1. Key country dynamics
    • 9.3.3.2. Competitive scenario
    • 9.3.3.3. Regulatory framework
    • 9.3.3.4. Reimbursement scenario
    • 9.3.3.5. Canada ureteral stents market estimates and forecasts, 2021 - 2033 (USD Million)
  • 9.3.4. Mexico
    • 9.3.4.1. Key country dynamics
    • 9.3.4.2. Competitive scenario
    • 9.3.4.3. Regulatory framework
    • 9.3.4.4. Reimbursement scenario
    • 9.3.4.5. Mexico ureteral stents market estimates and forecasts, 2021 - 2033 (USD Million)
• 9.4. Europe
  • 9.4.1. Europe ureteral stents market estimates and forecasts, 2021 - 2033 (USD Million)
  • 9.4.2. UK
    • 9.4.2.1. Key country dynamics
    • 9.4.2.2. Competitive scenario
    • 9.4.2.3. Regulatory framework
    • 9.4.2.4. Reimbursement scenario
    • 9.4.2.5. UK ureteral stents market estimates and forecasts, 2021 - 2033 (USD Million)
  • 9.4.3. Germany
    • 9.4.3.1. Key country dynamics
    • 9.4.3.2. Competitive scenario
    • 9.4.3.3. Regulatory framework
    • 9.4.3.4. Reimbursement scenario
    • 9.4.3.5. Germany ureteral stents market estimates and forecasts, 2021 - 2033 (USD Million)
  • 9.4.4. France
    • 9.4.4.1. Key country dynamics
    • 9.4.4.2. Competitive scenario
    • 9.4.4.3. Regulatory framework
    • 9.4.4.4. Reimbursement scenario
    • 9.4.4.5. France ureteral stents market estimates and forecasts, 2021 - 2033 (USD Million)
  • 9.4.5. Italy
    • 9.4.5.1. Key country dynamics
    • 9.4.5.2. Competitive scenario
    • 9.4.5.3. Regulatory framework
    • 9.4.5.4. Reimbursement scenario
    • 9.4.5.5. Italy ureteral stents market estimates and forecasts, 2021 - 2033 (USD Million)
  • 9.4.6. Spain
    • 9.4.6.1. Key country dynamics
    • 9.4.6.2. Competitive scenario
    • 9.4.6.3. Regulatory framework
    • 9.4.6.4. Reimbursement scenario
    • 9.4.6.5. Spain ureteral stents market estimates and forecasts, 2021 - 2033 (USD Million)
  • 9.4.7. Sweden
    • 9.4.7.1. Key country dynamics
    • 9.4.7.2. Competitive scenario
    • 9.4.7.3. Regulatory framework
    • 9.4.7.4. Reimbursement scenario
    • 9.4.7.5. Sweden ureteral stents market estimates and forecasts, 2021 - 2033 (USD Million)
  • 9.4.8. Denmark
    • 9.4.8.1. Key country dynamics
    • 9.4.8.2. Competitive scenario
    • 9.4.8.3. Regulatory framework
    • 9.4.8.4. Reimbursement scenario
    • 9.4.8.5. Denmark ureteral stents market estimates and forecasts, 2021 - 2033 (USD Million)
  • 9.4.9. Norway
    • 9.4.9.1. Key country dynamics
    • 9.4.9.2. Competitive scenario
    • 9.4.9.3. Regulatory framework
    • 9.4.9.4. Reimbursement scenario
    • 9.4.9.5. Norway ureteral stents market estimates and forecasts, 2021 - 2033 (USD Million)
• 9.5. Asia Pacific
  • 9.5.1. Asia Pacific ureteral stents market estimates and forecasts, 2021 - 2033 (USD Million)
  • 9.5.2. China
    • 9.5.2.1. Key country dynamics
    • 9.5.2.2. Competitive scenario
    • 9.5.2.3. Regulatory framework
    • 9.5.2.4. Reimbursement scenario
    • 9.5.2.5. China ureteral stents market estimates and forecasts, 2021 - 2033 (USD Million)
  • 9.5.3. Japan
    • 9.5.3.1. Key country dynamics
    • 9.5.3.2. Competitive scenario
    • 9.5.3.3. Regulatory framework
    • 9.5.3.4. Reimbursement scenario
    • 9.5.3.5. Japan ureteral stents market estimates and forecasts, 2021 - 2033 (USD Million)
  • 9.5.4. India
    • 9.5.4.1. Key country dynamics
    • 9.5.4.2. Competitive scenario
    • 9.5.4.3. Regulatory framework
    • 9.5.4.4. Reimbursement scenario
    • 9.5.4.5. India ureteral stents market estimates and forecasts, 2021 - 2033 (USD Million)
  • 9.5.5. South Korea
    • 9.5.5.1. Key country dynamics
    • 9.5.5.2. Competitive scenario
    • 9.5.5.3. Regulatory framework
    • 9.5.5.4. Reimbursement scenario
    • 9.5.5.5. South Korea ureteral stents market estimates and forecasts, 2021 - 2033 (USD Million)
  • 9.5.6. Australia
    • 9.5.6.1. Key country dynamics
    • 9.5.6.2. Competitive scenario
    • 9.5.6.3. Regulatory framework
    • 9.5.6.4. Reimbursement scenario
    • 9.5.6.5. Australia ureteral stents market estimates and forecasts, 2021 - 2033 (USD Million)
  • 9.5.7. Thailand
    • 9.5.7.1. Key country dynamics
    • 9.5.7.2. Competitive scenario
    • 9.5.7.3. Regulatory framework
    • 9.5.7.4. Reimbursement scenario
    • 9.5.7.5. Thailand ureteral stents market estimates and forecasts, 2021 - 2033 (USD Million)
• 9.6. Latin America
  • 9.6.1. Latin America ureteral stents market estimates and forecasts, 2021 - 2033 (USD Million)
  • 9.6.2. Brazil
    • 9.6.2.1. Key country dynamics
    • 9.6.2.2. Competitive scenario
    • 9.6.2.3. Regulatory framework
    • 9.6.2.4. Reimbursement scenario
    • 9.6.2.5. Brazil ureteral stents market estimates and forecasts, 2021 - 2033 (USD Million)
  • 9.6.3. Argentina
    • 9.6.3.1. Key country dynamics
    • 9.6.3.2. Competitive scenario
    • 9.6.3.3. Regulatory framework
    • 9.6.3.4. Reimbursement scenario
    • 9.6.3.5. Argentina ureteral stents market estimates and forecasts, 2021 - 2033 (USD Million)
• 9.7. Middle East and Africa
  • 9.7.1. Middle East and Africa ureteral stents market estimates and forecasts, 2021 - 2033 (USD Million)
  • 9.7.2. South Africa
    • 9.7.2.1. Key country dynamics
    • 9.7.2.2. Competitive scenario
    • 9.7.2.3. Regulatory framework
    • 9.7.2.4. Reimbursement scenario
    • 9.7.2.5. South Africa ureteral stents market estimates and forecasts, 2021 - 2033 (USD Million)
  • 9.7.3. Saudi Arabia
    • 9.7.3.1. Key country dynamics
    • 9.7.3.2. Competitive scenario
    • 9.7.3.3. Regulatory framework
    • 9.7.3.4. Reimbursement scenario
    • 9.7.3.5. Saudi Arabia ureteral stents market estimates and forecasts, 2021 - 2033 (USD Million)
  • 9.7.4. UAE
    • 9.7.4.1. Key country dynamics
    • 9.7.4.2. Competitive scenario
    • 9.7.4.3. Regulatory framework
    • 9.7.4.4. Reimbursement scenario
    • 9.7.4.5. UAE ureteral stents market estimates and forecasts, 2021 - 2033 (USD Million)
  • 9.7.5. Kuwait
    • 9.7.5.1. Key country dynamics
    • 9.7.5.2. Competitive scenario
    • 9.7.5.3. Regulatory framework
    • 9.7.5.4. Reimbursement scenario
    • 9.7.5.5. Kuwait ureteral stents market estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 10. Competitive Landscape

• 10.1. Recent Developments & Impact Analysis by Key Market Participants
• 10.2. Company Categorization
• 10.3. Company Market Share Analysis, 2025
• 10.4. Company Heat Map Analysis
• 10.5. Strategy Mapping
  • 10.5.1. Expansion
  • 10.5.2. Mergers & Acquisition
  • 10.5.3. Partnerships & Collaborations
  • 10.5.4. New Technology Launches
  • 10.5.5. Research And Development
  • 10.5.6. Company Profiles
  • 10.5.7. Becton, Dickinson and Company
    • 10.5.7.1. Company overview
    • 10.5.7.2. Financial performance
    • 10.5.7.3. Product Benchmarking
    • 10.5.7.4. Strategic initiatives
  • 10.5.8. Boston Scientific
    • 10.5.8.1. Company overview
    • 10.5.8.2. Financial performance
    • 10.5.8.3. Product Benchmarking
    • 10.5.8.4. Strategic initiatives
  • 10.5.9. B.Braun Melsungen AG
    • 10.5.9.1. Company overview
    • 10.5.9.2. Financial performance
    • 10.5.9.3. Product Benchmarking
    • 10.5.9.4. Strategic initiatives
  • 10.5.10. Allium Medical (Dahlhausen Group)
    • 10.5.10.1. Company overview
    • 10.5.10.2. Financial performance
    • 10.5.10.3. Product Benchmarking
    • 10.5.10.4. Strategic initiatives
  • 10.5.11. Coloplast
    • 10.5.11.1. Company overview
    • 10.5.11.2. Financial performance
    • 10.5.11.3. Product Benchmarking
    • 10.5.11.4. Strategic initiatives
  • 10.5.12. Olympus Corporation
    • 10.5.12.1. Company overview
    • 10.5.12.2. Financial performance
    • 10.5.12.3. Product Benchmarking
    • 10.5.12.4. Strategic initiatives
  • 10.5.13. Merit Medical Systems, Inc.
    • 10.5.13.1. Company overview
    • 10.5.13.2. Financial performance
    • 10.5.13.3. Product Benchmarking
    • 10.5.13.4. Strategic initiatives
  • 10.5.14. Pnn Medical A/S
    • 10.5.14.1. Company overview
    • 10.5.14.2. Financial performance
    • 10.5.14.3. Product Benchmarking
    • 10.5.14.4. Strategic initiatives
  • 10.5.15. Teleflex Incorporated.
    • 10.5.15.1. Company overview
    • 10.5.15.2. Financial performance
    • 10.5.15.3. Product Benchmarking
    • 10.5.15.4. Strategic initiatives
  • 10.5.16. Cook Medical
    • 10.5.16.1. Company overview
    • 10.5.16.2. Financial performance
    • 10.5.16.3. Product Benchmarking
    • 10.5.16.4. Strategic initiatives
  • 10.5.17. Well Lead Medical Co.,Ltd.
    • 10.5.17.1. Company overview
    • 10.5.17.2. Financial performance
    • 10.5.17.3. Product Benchmarking
    • 10.5.17.4. Strategic initiatives
  • 10.5.18. Urotech GmbH
    • 10.5.18.1. Company overview
    • 10.5.18.2. Financial performance
    • 10.5.18.3. Product Benchmarking
    • 10.5.18.4. Strategic initiatives
  • 10.5.19. optimed Medical Instruments GmbH
    • 10.5.19.1. Company overview
    • 10.5.19.2. Financial performance
    • 10.5.19.3. Product Benchmarking
    • 10.5.19.4. Strategic initiatives
  • 10.5.20. Advin Health Care
    • 10.5.20.1. Company overview
    • 10.5.20.2. Financial performance
    • 10.5.20.3. Product Benchmarking
    • 10.5.20.4. Strategic initiatives
  • 10.5.21. MEDpro Medical B.V.
    • 10.5.21.1. Company overview
    • 10.5.21.2. Financial performance
    • 10.5.21.3. Product Benchmarking
    • 10.5.21.4. Strategic initiatives